- Home
- IGMS vs ZYXI Comparison
IGMS vs ZYXI Comparison
Compare IGMS & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- ZYXI
- Stock Information
- Founded
- IGMS 1993
- ZYXI 1996
- Country
- IGMS United States
- ZYXI United States
- Employees
- IGMS N/A
- ZYXI N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- IGMS Health Care
- ZYXI Health Care
- Exchange
- IGMS Nasdaq
- ZYXI Nasdaq
- Market Cap
- IGMS 82.1M
- ZYXI 66.5M
- IPO Year
- IGMS 2019
- ZYXI N/A
- Fundamental
- Price
- IGMS $1.22
- ZYXI $2.18
- Analyst Decision
- IGMS Hold
- ZYXI Buy
- Analyst Count
- IGMS 8
- ZYXI 3
- Target Price
- IGMS $6.14
- ZYXI $10.25
- AVG Volume (30 Days)
- IGMS 167.6K
- ZYXI 262.3K
- Earning Date
- IGMS 05-07-2025
- ZYXI 04-29-2025
- Dividend Yield
- IGMS N/A
- ZYXI N/A
- EPS Growth
- IGMS N/A
- ZYXI N/A
- EPS
- IGMS N/A
- ZYXI 0.09
- Revenue
- IGMS $2,679,000.00
- ZYXI $192,354,000.00
- Revenue This Year
- IGMS $121.76
- ZYXI N/A
- Revenue Next Year
- IGMS $46.83
- ZYXI $23.16
- P/E Ratio
- IGMS N/A
- ZYXI $24.22
- Revenue Growth
- IGMS 25.77
- ZYXI 4.36
- 52 Week Low
- IGMS $0.92
- ZYXI $1.93
- 52 Week High
- IGMS $22.50
- ZYXI $12.19
- Technical
- Relative Strength Index (RSI)
- IGMS 47.65
- ZYXI 26.14
- Support Level
- IGMS $1.16
- ZYXI $2.03
- Resistance Level
- IGMS $1.31
- ZYXI $2.24
- Average True Range (ATR)
- IGMS 0.12
- ZYXI 0.18
- MACD
- IGMS 0.03
- ZYXI 0.17
- Stochastic Oscillator
- IGMS 76.92
- ZYXI 38.46
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.